CD81 and glioblastoma: Meanwhile, TNC+/CD81+ plasma EVs showed the highest counts inall analyzed groups (tumor and nontumor) and the weakest (but stillsignificant) fold changes in glioblastoma, aligning with our findingson TNC+/CD81+ levels in tissue-derived EVs andthe unspecific spatial expression of CD81 in brain tissue (particularlyfrom myeloid cells).